A pH-responsive liposomal system for delivery of DOX and tazemetostat was developed and evaluated <i>in vivo</i>.<h4>Results</h4>EZH2 was highly expressed in breast cancer and correlated with poor clinical outcomes. This evidence concerns the gene EZH2 and breast carcinoma.